Biotech News

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Cyclerion (CYCN)Cyclerion2024-08-07 11:00 ESTCompany update

CAMBRIDGE, Mass. , Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul , Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December

Related news

NBIXNeurocrine Biosciences2026-07-21 20:05 EST

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

View all latest news

Cyclerion

Cyclerion was a biotechnology company focused on cyclic nucleotide biology and central nervous system or vascular-related disease programs before becoming a historical ticker. Its story reflected the challenge of turning a mechanistic platform into a durable drug franchise.

Recent company news

CYCNCyclerion2026-04-01 11:05 EST

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

CYCNCyclerion2026-02-17 12:00 EST

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

CYCNCyclerion2026-01-05 21:01 EST

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

CYCNCyclerion2025-09-23 20:01 EST

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

CYCNCyclerion2024-12-17 13:08 EST

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Stock data

Close: 3.89 USD
Market cap: 13.08M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States